Blue Trust Inc. Acquires 8,039 Shares of UiPath Inc. (NYSE:PATH)

Blue Trust Inc. lifted its holdings in shares of UiPath Inc. (NYSE:PATH) by 36.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,085 shares of the healthcare company’s stock after purchasing an additional 8,039 shares during the quarter. Blue Trust Inc.’s holdings in UiPath were worth $381,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in UiPath by 5.6% in the first quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock valued at $911,741,000 after acquiring an additional 2,133,078 shares during the last quarter. Pacer Advisors Inc. bought a new position in UiPath in the second quarter valued at approximately $69,180,000. Dimensional Fund Advisors LP increased its stake in UiPath by 37.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,783,571 shares of the healthcare company’s stock valued at $35,296,000 after acquiring an additional 754,519 shares during the last quarter. Bank of New York Mellon Corp increased its stake in UiPath by 20.8% in the second quarter. Bank of New York Mellon Corp now owns 2,552,921 shares of the healthcare company’s stock valued at $32,371,000 after acquiring an additional 439,344 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in UiPath by 120.6% in the second quarter. AQR Capital Management LLC now owns 1,633,393 shares of the healthcare company’s stock valued at $20,385,000 after acquiring an additional 892,845 shares during the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PATH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of UiPath in a research note on Wednesday. TD Cowen decreased their target price on shares of UiPath from $17.00 to $16.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. BMO Capital Markets boosted their target price on shares of UiPath from $14.00 to $15.00 and gave the stock a “market perform” rating in a research note on Friday, September 6th. JPMorgan Chase & Co. decreased their target price on shares of UiPath from $19.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Wells Fargo & Company decreased their target price on shares of UiPath from $15.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Sixteen equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, UiPath has a consensus rating of “Hold” and a consensus target price of $17.47.

UiPath Trading Down 4.6 %

Shares of NYSE PATH opened at $12.06 on Thursday. The firm’s 50-day moving average price is $12.46 and its 200-day moving average price is $14.24. UiPath Inc. has a 1-year low of $10.37 and a 1-year high of $27.87. The firm has a market capitalization of $6.91 billion, a P/E ratio of -75.38 and a beta of 0.88.

UiPath (NYSE:PATH) last posted its earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. The company had revenue of $316.00 million during the quarter, compared to the consensus estimate of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.09) earnings per share. Equities research analysts forecast that UiPath Inc. will post -0.23 EPS for the current year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the completion of the sale, the chief financial officer now directly owns 849,917 shares of the company’s stock, valued at approximately $10,258,498.19. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 22.37% of the stock is currently owned by insiders.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.